Real World Study of Lapatinib Among Metastatic Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT03894410
- Lead Sponsor
- Fudan University
- Brief Summary
A multicenter, retrospective, real world study of Lapatinib among Metastatic Breast Cancer (MBC) Patients in Clinical Practice.
- Detailed Description
This study collected patients used Lapatinib-base therapy among MBC, and tried to figure out if there was difference between single anti-Her2 treatment and dual anti-Her2 treatment. Furthermore, this study investigated the treatment after Lapatinib.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 242
Inclusion Criteria
- Patients who were treated with Lapatinib between June 2014 to June 2018.
- Patients experienced progression on prior trastuzumab-containing regimens and a taxane.
- Complete medical history was available.
Read More
Exclusion Criteria
- Medical history was incomplete.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) 6 weeks PFS 6 weeks Progression free survival
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China